The l-Ser analog #290 promotes bone recovery in OP and RA mice

Anton Bahtiar, Takashi Nakamura, Koichi Kishida, Junpei Katsura, Mai Nitta, Norihiro Ishida-Kitagawa, Takuya Ogawa, Tatsuo Takeya

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


We previously characterized the l-Ser analog #290, H(tBut)-l-Ser-O- Methyl·HCl, as a novel inhibitor of osteoclastogenesis which functions in both mouse and human cells. Here, we assessed the activity of #290 in animal models of osteoporosis and rheumatoid arthritis. Treatment of animals with #290 both prevented bone loss and led to the recovery of lost bone in osteoporotic mice. When inflammatory arthritis was induced in SKG mice, #290 treatment suppressed arthritis scores and significantly prevented the destruction of calcaneous bones. Additionally, #290 reciprocally modulated the mammalian target of rapamycin (mTOR) pathway in osteoclasts and osteoblasts in vitro, suggesting a dual effect on bone homeostasis. Our results demonstrate that #290 is a potential novel therapeutic tool for the treatment and/or study of diseases associated with bone destruction.

Original languageEnglish
Pages (from-to)203-209
Number of pages7
JournalPharmacological Research
Issue number3
Publication statusPublished - Sept 2011


  • Bone loss and recovery
  • Mouse models
  • Osteoblastic cells
  • Osteoclastogenesis inhibitor
  • l-Ser analog
  • mTOR


Dive into the research topics of 'The l-Ser analog #290 promotes bone recovery in OP and RA mice'. Together they form a unique fingerprint.

Cite this